Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say.
The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging.
The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert.
"When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve."
Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm.
The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver.
Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth.
About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance.
Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells.
In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo.
The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival.
No new side effects were reported and few patients from either group dropped out due to side effects.
"This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say.
The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging.
The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert.
"When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve."
Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm.
The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver.
Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth.
About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance.
Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells.
In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo.
The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival.
No new side effects were reported and few patients from either group dropped out due to side effects.
"This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say.
The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging.
The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert.
"When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve."
Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm.
The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver.
Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth.
About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance.
Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells.
In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo.
The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival.
No new side effects were reported and few patients from either group dropped out due to side effects.
"This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say.
The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging.
The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert.
"When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve."
Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm.
The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver.
Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth.
About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance.
Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells.
In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo.
The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival.
No new side effects were reported and few patients from either group dropped out due to side effects.
"This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
7NEWS
11 hours ago
- 7NEWS
Australian breakthrough blood test offers hope for early ovarian cancer detection
An Australian developed blood test for cancer is being hailed as a potential lifesaver for thousands of women, with promising results unveiled at a major international medical conference. In a groundbreaking announcement at the American Society of Clinical Oncology (ASCO) conference in the United States, Australian scientists revealed the revolutionary blood test can detect ovarian cancer in its earliest-and most treatable-stages. Developed in a Melbourne laboratory, the INNOVIQ EXO-OC™ Test has shown remarkable accuracy in trials. Its key highlights include: 77 per cent sensitivity at 99.6 per cent specificity for detecting ovarian cancer across all stages, surpassing globally accepted clinical performance criteria for population screening. Detected all early-stage cancers (Stage I and II) with no missed diagnoses-a critical advancement in addressing the unmet need for accurate and reliable early detection in asymptomatic, average-risk women. 'This will be a world-first,' Dr Leearne Hinch, the CEO of the company told 7NEWS. 'Our test will enable many women's lives to be saved globally.' Professor Greg Rice, from the University of Queensland, who played a key role in the development of the test, confirmed the breakthrough. 'In the most recent tests that we completed, the EXO-OC™ test correctly identified all early stage ovarian cancers,' he told 7NEWS. Ovarian cancer is often called the 'silent killer' as it is usually asymptomatic in the early stages of disease. For women like Emily Jol, the test could have made a life-changing difference. It took six months for her to receive a diagnosis after being told an ovarian cyst found during a routine ultrasound was 'completely normal.' 'There was nothing wrong with it, they said. It was just part of being a woman,' Emily recalled to 7NEWS. Just 21-years-old at the time, she continued to push for answers and eventually, surgery revealed the truth: she had ovarian cancer. Fortunately, it was caught before it spread. 'I still consider myself to be really, really lucky,' she said. That's a rare outcome as currently, most ovarian cancer cases are diagnosed too late. One Australian woman dies from the disease every eight hours. Because it's often diagnosed at a late stage, after symptoms have appeared, the survival rate beyond five years can be as little as 30 per cent. But with the new test, scientists believe that survival rate could soar to over 90 percent. 'We're very proud that this is Australian science,' said Dr Hinch. The test is still undergoing further evaluation, but if all goes well, it could receive regulatory, FDA, approval in the United States soon, and hit the global market within two to three years. A message of hope where little existed before. It was partly funded by the Ovarian Cancer Research Foundation.
Herald Sun
3 days ago
- Herald Sun
Lumos passes milestone in CLIA waiver
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Lumos enrols 61 of required 120 bacterial positive patients in US CLIA waiver clinical study for FebriDx Study to be completed by Q4 2025 with US FDA CLIA waiver application to be submitted in October 2025 Successful CLIA waiver would unlock access to a US total addressable market exceeding US$1 billion Special Report: Lumos Diagnostics has passed a major milestone in a US CLIA waiver study for its rapid point-of-care diagnostic FebriDx designed to differentiate between bacterial and non-bacterial acute respiratory infections. Developer of rapid, point-of-care testing Lumos Diagnostics (ASX:LDX) has achieved 61 bacterial positive patients representing 50% of the target of 120 bacterial positive patient results required for its ongoing CLIA waiver study. Lumos said there had been 439 patients enrolled in the study and testing of the 500th patient would trigger a US$298,457 milestone payment from its partner, the Biomedical Advanced Research and Development Authority (BARDA). The bacterial prevalence rate in the study so far is at an average of 14% (61/439). However, since Lumos implemented its enrichment strategy in late March the company said the bacterial prevalence rate in the trial had been around 35%. This study is a critical step towards securing a CLIA waiver from the US Food and Drug Administration (FDA). It would enable FebriDx to be used in a broader range of healthcare settings, including physician offices, urgent care clinics or other outpatient clinics that do not operate under high-complexity laboratory certification. At the current accrual rate, Lumos said the study was anticipated to conclude in Q4 2025. Subject to successful data outcomes, Lumos expects to submit its CLIA waiver application to the FDA in Q4 2025. Addressing overuse of antibiotics FebriDx is a unique, rapid test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a simple fingerstick blood sample, delivering results quickly at the point-of-care. The test enables clinicians to make more informed treatment decisions at the initial point of care, supporting appropriate antibiotic stewardship and helping to combat the global challenge of antimicrobial resistance. By aiding clinicians in faster, better decisions at the point-of-care, Lumos said FebriDx had the potential to improve patient outcomes, reduce unnecessary antibiotic prescriptions, and lower overall healthcare costs. The World Health Organization has warned that the global surge in antibiotic resistance is undermining the effectiveness of commonly used antibiotics to treat widespread bacterial infections. Lumos said in the US antibiotic-resistant infections caused ~2.8 million illnesses and 35,000 deaths each year. 'Encouraged by the progress' Managing director Doug Ward said reaching the halfway mark in bacterial positive patient recruitment for its CLIA waiver clinical study was an important achievement for Lumos. 'We are encouraged by the progress of the study with the support of BARDA and remain focused on delivering a successful outcome that expands the availability of FebriDx to clinicians and patients across the US,' he said. "A successful CLIA waiver would unlock access to a US total addressable market exceeding US$1 billion and significantly expand the commercial potential for FebriDx in point-of-care settings by up to 15 times our current available market opportunity." He said the company continues to work closely with its clinical partners to complete enrolment and data collection in a timely manner. Lumos recently announced it had Medicare reimbursement from six of seven Medicare administrative contractors, representing more than 85% of total US Medicare payment coverage. This article was developed in collaboration with, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Lumos passes milestone in CLIA waiver study for point-of-care respiratory test
Sydney Morning Herald
3 days ago
- Sydney Morning Herald
China's latest boom is sounding alarm bells in America
It marked a watershed moment for the pharmaceutical sector, which had long written off China as a nation that excelled in drug manufacturing and 'copycat' treatments but not medicine discovery. Akeso's debut on the world stage has been described as a 'DeepSeek' moment for the industry – a reference to the sudden emergence of a highly advanced AI chatbot out of China earlier this year, which took US tech giants by surprise and wiped close to $US1 trillion ($1.5 trillion) off global stock markets. Summit's shares are up more than 600 per cent since first announcing the lung cancer trial results. 'The two large innovators in our industry today are the US and China,' Sir Pascal Soriot, the boss of AstraZeneca, said in March. 'China is, I think over the next five to 10 years, going to emerge as really a driving force for innovation in our sector.' It sets the stage for a growing tussle between the US and China over the future of drug development. Donald Trump has been clear that he wants pharmaceutical giants to be investing more in America. Biopharmaceutical companies and their suppliers account for 4.9 million jobs and are worth around $US1.65 trillion ($2.6 trillion) to the US. However, drug companies are increasingly turning east when it comes to investing in new drugs and clinical trials. Not only is China becoming an easier place to research and create new drugs, but the Trump administration is also shaking faith in the US. Vaccine sceptic health secretary Robert F Kennedy Jr has prompted much anxiety in the industry. By contrast, China is 'very business friendly and stable' Novartis boss Vas Narasimhan said in May. Drugs boom Beijing has been attempting to win more pharma investment for years – and specifically attempting to boost funding for drug innovation. Drug discovery was a key pillar of the 'Healthy China 2030″ strategy unveiled in 2016, aimed at helping the country cope with its ageing population. Loading The focus has already paid dividends. Over the past three years alone, the number of Chinese drugs in development has doubled to 4,391. Almost half are either novel drugs or something known as a 'fast-follower', where treatments are quickly developed on the back of breakthroughs by rivals. According to Barclays, the number of so-called 'first-in-class' drugs under development in China rose to around 120 last year, having been in the single digits in 2015. First-in-class essentially measures the level of innovation by looking at the highest development stage a drug has reached and the earliest time it reached that stage. The growth in China is unmatched. While the US, which has long been regarded as the world leader in drug discovery, has more first-in-class drugs in development, at 151, the growth rate has been much slower. 'The shift isn't incremental, it's tectonic,' says Abhishek Jha, the founder of life sciences data company Elucidata. One crucial part of Beijing's push to drive more drug discovery has been speeding up clinical trials. In China, regulators allow businesses to get studies up and running quicker, and then update them as they progress. This can provide early data on new drugs, which is a major draw for multinational companies looking for novel treatments that show signs of working well. It has sparked a boom in studies taking place in China. According to figures from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), China accounted for around 18 per cent of clinical trials sponsored by companies in 2023 compared to just 5 per cent in 2013. Meanwhile, the US proportion has dipped from 28 per cent to 23 per cent. Clinical trial enrolment in China is surging, with around 40 per cent now having more than 100 participants. Bitter pill Fewer regulatory barriers are just one of a number of reasons pharma companies are turning to China. Workers, too, are less averse to working unsociable hours than they would be in Western nations. Shirley Chen, a Barclays analyst, says: 'Chinese scientists may be happier to accept very long work hours and people like hospital personnel [where trials take place] are actually okay to do night shifts.' Major drug giants are now scouring China for potential deals. The likes of GSK, AstraZeneca and Merck have all struck deals worth more than $US1 billion to get the rights to develop and sell Chinese drugs outside the country. The rise of China's pharmaceutical industry has started to raise alarm bells in the US. Trump may be focused on returning manufacturing jobs to the US, yet some say he should be concerned that more high-quality jobs and research posts are starting to drift to China. 'Five years ago, US pharmaceutical companies didn't license any new drugs from China,' Scott Gottlied, the former Food and Drug Administration commissioner, wrote earlier this month. 'By 2024, one third of their new compounds were coming from Chinese biotechnology firms.' He warned that the shift of clinical trials to Asia could undermine innovation in the US as companies choose to 'divert funds that might otherwise bolster innovation hubs such as Boston's Kendall Square or North Carolina's Research Triangle'. Loading 'The US biotechnology industry was the world's envy, but if we're not careful, every drug could be made in China.' While Trump exempted most countries' pharmaceutical industries from tariffs in his 'liberation day' blitz, China was not spared. That means physically manufacturing drugs for the US in China is out of the question, for now at least.
